Hetero

Hetero Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest produc

Hetero is one of India’s leading generic pharmaceutical companies and world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Having 20+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas include APIs, Formulations, Biosimilars and Custom Pharmaceutical Services (CPS). The company is recognized for its strengths in Research and Development, Manufacturing and Commercialization of a wide range of products around the world. Hetero has 25+ state-of-the-art manufacturing facilities strategically located worldwide. And a majority of these facilities have been approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC - South Africa among others. We are endowed with a robust portfolio of above 200 products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, etc. Hetero has a strong global presence in 120+ countries and focusses on making affordable medicines accessible to patients worldwide.

31/12/2025

As we reflect on a year defined by progress and purpose, Hetero extends its heartfelt appreciation to partners, caregivers, and communities who walked this journey with us.
As we step into 2026, we reaffirm our commitment to expanding access to affordable, life-saving medicines and advancing health for all.
Wishing you and your loved ones a year ahead filled with strength, hope, and good health.

31/12/2025

Hetero marked its presence at the ESMO Asia Congress in Singapore, reinforcing its commitment to advancing oncology care across Asia. With participation from 4,550+ delegates across 70+ countries, the congress highlighted its growing global relevance.

Building on four years of engagement, Hetero showcased its expanding footprint and focus on affordable oncology solutions. Insights from physician interactions and country discussions continue to guide long-term growth across key Asian markets.

25/12/2025

Spreading the magic of Christmas across our global Hetero family!

From vibrant decorations and joyful gatherings in our offices worldwide, we’re celebrating the season of togetherness, gratitude, and hope.

Wishing you and your loved ones a joyful and peaceful Christmas from the entire Hetero team.

May this festive season bring warmth, laughter, and cherished moments.

As we conclude another remarkable year, we extend our sincere appreciation to all who have been part of our journey and ...
20/12/2025

As we conclude another remarkable year, we extend our sincere appreciation to all who have been part of our journey and shared in our vision.

This festive season, we reaffirm our purpose and remain committed to advancing health, hope, and well-being for everyone everywhere.

Wishing you and your loved ones a joyous holiday season and a new year filled with peace, prosperity, and good health.

19/12/2025

ASCEND (Academy by Sindhu for Cancer Education and New Developments) is a first-of-its-kind global initiative by Hetero, in collaboration with Sindhu Hospitals, aimed at advancing excellence and precision in cancer care.

We are proud to share the successful completion of ASCEND 1.0 – East Africa, designed to strengthen oncology capacity across Africa through rigorous academic training and hands-on exposure to the latest advancements in cancer treatment for oncology specialists.

The inaugural program saw 13 oncologists successfully complete the cohort, with participants from Kenya, Tanzania, and Uganda, who underwent intensive classroom learning at Sindhu Hospitals, received hands-on training with state-of-the-art oncology technologies, and gained firsthand exposure to scientific innovation at Hetero’s world-class Biopharma manufacturing facility.

This prestigious program is recognized and approved by the Telangana State Medical Council (TSMC), India, with all participants receiving formal certification and TSMC registration upon completion.

ASCEND reflects our shared commitment to building global oncology expertise and improving access to quality cancer care across regions.

18/12/2025

Hetero participated in ICASA 2025, held in Ghana from 3–8 December—one of Africa’s foremost platforms for dialogue on HIV/AIDS, public health innovation, and global health partnerships. Our experience at ICASA 2025 reinforces our commitment to strengthening global health partnerships and advancing public health outcomes.


12/12/2025

At Hetero, every action we take is guided by a single belief — that life-saving medicines must be accessible and affordable for all. This purpose drives us every day.



On Universal Health Coverage Day, we reaffirm our commitment to advancing SDG 3 by enabling access to quality, affordable healthcare for everyone, everywhere.



03/12/2025

Glimpses from our last week , CPHI India!
We’re carrying forward the energy and momentum from meaningful collaborations and insightful conversations with the pharmaceutical community - fueling our shared mission to advance patient outcomes through life-saving and affordable therapeutics worldwide.

01/12/2025

We’ve come a long way in responding to the AIDS crisis — to a point where prevention truly can be better than cure. Preventive medicines like pre-exposure prophylaxis (PrEP) can reduce the risk of acquiring HIV by up to 99% when taken consistently. This is one of the most important breakthroughs in public health.



But progress only matters if it reaches everyone, everywhere. That demands a collective will to ensure affordable, life-saving treatment and prevention for all.



This World AIDS Day, we at Hetero reaffirm our commitment to making an AIDS-free world possible.

H

We’re delighted to be at ICASA 2025 – Africa’s largest convening dedicated to reducing the impact of HIV/AIDS, Tuberculo...
01/12/2025

We’re delighted to be at ICASA 2025 – Africa’s largest convening dedicated to reducing the impact of HIV/AIDS, Tuberculosis, Hepatitis and Malaria, and championing social justice and equitable access to treatment.

At Hetero, advancing patient outcomes through the manufacturing and supply of life-saving, affordable antiretroviral (ARV) APIs and finished formulations is at the heart of what we do every day.

Visit us to explore how we can work together to help end AIDS as a global health threat by 2030.

Booth 3 | 3–8 December 2025 | Accra International Conference Centre, Ghana


What an inspiring 3 days for us hashtag , CPHI & PMEC India! The meaningful collaborations and insightful conversations ...
27/11/2025

What an inspiring 3 days for us hashtag , CPHI & PMEC India!

The meaningful collaborations and insightful conversations with the pharmaceutical community are driving us forward in our shared mission: advancing patient outcomes through life-saving and affordable therapeutics worldwide.

Address

7-2-A2, Hetero Corporate Industrial Estates, Sanath Nagar
Hyderabad
500018

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm
Saturday 9am - 6pm

Telephone

+914023704923

Website

Alerts

Be the first to know and let us send you an email when Hetero posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hetero:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.